Concurrent Administration of Interferon Alfa-2b and Beta-1a

Author:

Tanvetyanon Tawee1,Stadtmauer Edward A2,Kerson Lawrence A3

Affiliation:

1. Tawee Tanvetyanon MD, at time of writing, Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA; now, Fellow in Hematology/Oncology, Loyola University Medical Center, Maywood, IL

2. Edward A Stadtmauer MD, Associate Professor, Director of Bone Marrow and Stem Cell Transplant Program, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia

3. Lawrence A Kerson MD, Associate Clinical Professor, Department of Neurology, University of Pennsylvania Medical Center

Abstract

OBJECTIVE To describe the concurrent use of interferon (IFN) alfa and beta in a patient with multiple sclerosis (MS) and chronic myeloid leukemia (CML). CASE SUMMARY A 60-year-old white man developed CML while receiving IFN beta-1a treatment for MS. The patient was started on IFN alfa-2b 1 million units 3 times weekly with IFN beta-1a 30 μg weekly. The dosage of IFN alfa was increased to 3 million units/d 1 month later. He achieved complete hematologic remission in 3 months. The observed adverse effects were mild and included fatigue, somnolence, weight loss, and difficulty with memory. At 19 months after treatment, the patient remained in hematologic remission and his expanded disability status scale score remained unchanged. DISCUSSION Concomitant treatment with interferon alfa and beta by a gradual increase in the dosage of IFN alfa was well tolerated. Although imatinib mesylate may be a preferred treatment for patients with CML and MS at this time, our experience with safe concurrent use of IFN alfa and beta may benefit other patients who require this combined treatment. CONCLUSIONS Concurrent administration of interferon alfa-2b and beta-1a was well tolerated by our patient with CML and MS.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3